Is Standard BioTools profitable in 2026?

No. Standard BioTools posted a FY2025 adjusted EBITDA loss of $62.6 million on revenue of $85.3 million, down 6% year over year, per its Feb 24, 2026 earnings release. FY2026 guidance targets $80-85 million revenue with losses narrowing toward breakeven, but the company remains unprofitable.

Is Standard BioTools being acquired?

It is reverse merging into Treeline Biosciences, a private oncology drug developer. The definitive all-stock deal, signed June 8, 2026, gives existing Standard BioTools shareholders only about 16% of the combined company, renamed Treeline Biosciences Holdings (TRLN), targeted to close in second half 2026.

Who owns Standard BioTools stock?

As of filings through mid-2026, Casdin Capital holds roughly 22-23% combined and Viking Global Investors about 15%, both stemming from a 2022 $250 million PIPE investment that triggered the Fluidigm-to-Standard BioTools rebrand.

Could AI replace Standard BioTools' mass cytometry business?

Not directly. AI threatens the downstream analytics layer, like clustering CyTOF or Hyperion data, but cannot replace the physical wet-lab measurement step requiring proprietary DVS mass cytometry instruments and reagents. The bigger threat is consolidation by Bruker and Quanterix, not AI displacement.

Who is Standard BioTools' biggest competitor?

Quanterix, which acquired rival spatial biology firm Akoya Biosciences in a deal closed July 9, 2025, and Bruker Corporation, which has rolled up Canopy Biosciences and PhenomeX (~$108M, 2023), both consolidating the single-cell and spatial proteomics space Standard BioTools competes in.

What happened to Standard BioTools' SomaLogic business?

Standard BioTools acquired SomaLogic in an all-stock merger completed January 5, 2024, then reversed course, selling SomaLogic assets to Illumina for up to $425 million ($350 million upfront), a deal announced June 2025 and closed January 30, 2026.

Biotech tools companies · acquisition pending · United States

Standard BioTools

standardbio.com ↗

Mass cytometry and microfluidics tools maker now merging into an oncology drug developer.

Little protection left

Assessed 24 July 2026 · Evidence as of 24 July 2026

Not much stands between this business and its pressures.

On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Treeline Biosciences reverse-merger shareholder vote and SEC review of S-4

The call

The tools business is shrinking and consolidating around it while shareholders wait to become minority owners of an unrelated oncology drug developer.

Standard BioTools makes machines that count and study individual cells in blood and tissue samples, selling them to research labs and hospitals. The company is being absorbed into Treeline Biosciences, an oncology (cancer drug) company, which means the tools business will shrink and its current owners will own only a small slice of the new combined company focused on drugs instead. Bigger competitors like Bruker, Quanterix, and Illumina are already buying up similar cell-analysis businesses, so even if the tools stayed independent, it would face intense pressure from larger, better-funded rivals; the main thing that could change the picture is whether Treeline's cancer drug pipeline actually works in clinical trials, but that is completely separate from the tools business you would be working in.

Why

AI pressure: None apparent. AI can speed up analysis of CyTOF data but cannot replace the wet-lab measurement step Standard BioTools sells. Could AI do the core job? Only partly.

Bigger players: Bruker, Quanterix, and Illumina consolidating spatial/single-cell tools. Quanterix bought Akoya, Bruker rolled up Canopy and PhenomeX, and Illumina already bought Standard BioTools' own SomaLogic unit. Could a giant copy it? Yes, easily.

What protects it. None left in tools; the company voted to exit the space via merger rather than compete for share.

What would change this call

Treeline Biosciences merger closes or is voted down (S-4, target H2 2026). Shows whether the tools business is wound down into an unrelated oncology bet.
Consumables revenue trend in FY2026 quarterly reports. Shows whether customer attrition to Bruker/Quanterix/Illumina is continuing or stabilizing.
Illumina's remaining SomaLogic earnout payments (up to $75M) hit or missed. Shows whether the divested proteomics asset is performing under a larger incumbent.

Key numbers

FY2025 revenue $85.3M, down 6% year over year (2025-12-31)
FY2025 adjusted EBITDA loss $62.6M (2025-12-31)
Existing shareholders get ~16% of merged Treeline entity (2026-06-08)

Named risks

Treeline reverse merger could fail shareholder or regulatory approval, leaving strategy in limbo. Severity: high
If merger closes, existing shareholders hold only ~16% of an unrelated, unvetted oncology pipeline. Severity: high
Consumables revenue decline (down 11% in FY2025) signals eroding installed-base engagement. Severity: high
Continued industry consolidation (Quanterix/Akoya, Bruker) shrinks addressable independent market for LAB's tools. Severity: medium
Two rounds of layoffs (2024, 2025) indicate ongoing operational instability and talent attrition. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Quanterix (with Akoya Biosciences)	losing to	Quanterix closed Akoya acquisition Jul 9, 2025, gaining integrated blood-to-tissue biomarker platform scale
Bruker Corporation	losing to	Bruker rolled up Canopy Biosciences (2020) and PhenomeX (~$108M, 2023) to build competing spatial/single-cell portfolio
Illumina	losing to	Illumina acquired SomaLogic proteomics assets from Standard BioTools itself, closing Jan 30, 2026, becoming a scale multi-omics rival
Thermo Fisher, Danaher, Agilent	losing to	Larger diversified instrument makers can bundle competing cytometry and proteomics workflows against sub-scale ~$85M revenue LAB

Questions people ask

Is Standard BioTools profitable in 2026?: No. Standard BioTools posted a FY2025 adjusted EBITDA loss of $62.6 million on revenue of $85.3 million, down 6% year over year, per its Feb 24, 2026 earnings release. FY2026 guidance targets $80-85 million revenue with losses narrowing toward breakeven, but the company remains unprofitable.
Is Standard BioTools being acquired?: It is reverse merging into Treeline Biosciences, a private oncology drug developer. The definitive all-stock deal, signed June 8, 2026, gives existing Standard BioTools shareholders only about 16% of the combined company, renamed Treeline Biosciences Holdings (TRLN), targeted to close in second half 2026.
Who owns Standard BioTools stock?: As of filings through mid-2026, Casdin Capital holds roughly 22-23% combined and Viking Global Investors about 15%, both stemming from a 2022 $250 million PIPE investment that triggered the Fluidigm-to-Standard BioTools rebrand.
Could AI replace Standard BioTools' mass cytometry business?: Not directly. AI threatens the downstream analytics layer, like clustering CyTOF or Hyperion data, but cannot replace the physical wet-lab measurement step requiring proprietary DVS mass cytometry instruments and reagents. The bigger threat is consolidation by Bruker and Quanterix, not AI displacement.
Who is Standard BioTools' biggest competitor?: Quanterix, which acquired rival spatial biology firm Akoya Biosciences in a deal closed July 9, 2025, and Bruker Corporation, which has rolled up Canopy Biosciences and PhenomeX (~$108M, 2023), both consolidating the single-cell and spatial proteomics space Standard BioTools competes in.
What happened to Standard BioTools' SomaLogic business?: Standard BioTools acquired SomaLogic in an all-stock merger completed January 5, 2024, then reversed course, selling SomaLogic assets to Illumina for up to $425 million ($350 million upfront), a deal announced June 2025 and closed January 30, 2026.

Timeline

2026-07-20Standard BioTools files S-4 registration for Treeline Biosciences merger
2026-06-08Definitive all-stock merger agreement signed with Treeline Biosciences, ~16% stake for LAB holders
2026-02-24FY2025 results: $85.3M revenue (down 6%), adjusted EBITDA loss $62.6M
2026-01-30Completed sale of SomaLogic assets to Illumina for up to $425M
2025-09-17Announced further 15% global workforce cut
2025-07-09Quanterix completed acquisition of rival Akoya Biosciences
2025-06-23Announced strategic sale of SomaLogic to Illumina
2024-04-25Announced 10% staff layoff, expected $45-50M annual savings
2024-01-05Completed all-stock merger with SomaLogic
2022Rebranded from Fluidigm to Standard BioTools after $250M PIPE

Revision history

24 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Singular Genomics Synthego Corporation T2 Biosystems, Inc.